A Phase 2a, Multi-Center, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Evaluate the Safety and Efficacy of MEM 3454 as Adjunctive Treatment in Combination With a Preexisting Antipsychotic in Patients With Cognitive Impairment Associated With Schizophrenia

Trial Profile

A Phase 2a, Multi-Center, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Evaluate the Safety and Efficacy of MEM 3454 as Adjunctive Treatment in Combination With a Preexisting Antipsychotic in Patients With Cognitive Impairment Associated With Schizophrenia

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 01 Jun 2014

At a glance

  • Drugs RG 3487 (Primary)
  • Indications Schizophrenia
  • Focus Therapeutic Use
  • Sponsors Memory Pharmaceuticals
  • Most Recent Events

    • 05 Dec 2008 Status changed from recruiting to active, no longer recruiting, based on information from ClinicalTrials.gov.
    • 19 Nov 2008 Target accrual achieved; 212 patients randomised according to a Memory Pharmaceuticals media release.
    • 26 Sep 2008 Added ref.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top